XTalks

APRIL 17, 2023

In clinical trials, patients experienced significantly clearer skin and less interference with sleep due to itch when taking lebrikizumab compared to placebo. The ADvocate1 and ADvocate2 Phase III studies were published in the New England Journal of Medicine and the British Journal of Dermatology , respectively.

Dermatology 97

Dermatology Antibody Clinical Trials Clinical Trials 97

XTalks

MAY 19, 2023

Clinical trials play a vital role in advancing patient treatment and medical care. This article delves into ten trends and statistics in the world of clinical trials for 2023. And don’t forget to explore the upcoming webinars about clinical trials on Xtalks to see what piques your curiosity about the latest clinical trial solutions.

Clinical Trials 97

Clinical Trials Clinical Trials Trials Clinical Research 97

Pharmaceutical Technology

APRIL 17, 2023

The company will provide regulatory advice to Incannex, and manage clinical trials to develop CannQuit and ReneCann products to treat addiction and immune-disordered skin diseases. The company will help in managing the clinical trials of the products once the regulators provide approvals for the proposed research and development programmes.

Dermatology 130

Dermatology Clinical Trials Clinical Trials Production 130

Pharmaceutical Technology

MAY 19, 2023

The FDA nod means Rinvoq is now approved for seven indications in gastroenterology, rheumatology and dermatology. A maintenance study showed the same effects at 52 weeks. Clinical response was observed after just two weeks in some cases. In patients with severe symptoms, a dosage of 30mg can be considered.

FDA Approval 264

FDA Approval Dermatology Sales Clinical Trials 264

Pharmaceutical Technology

FEBRUARY 28, 2023

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR).

Generic Pharmaceutical 172

Generic Pharmaceutical Dermatology Clinical Trials Clinical Trials 172

pharmaphorum

JULY 8, 2022

The COVID-19 pandemic has catalysed significant changes in the way pharma develops drugs, particularly in the clinical trial space. Hybrid or decentralised clinical trials (DCTs) have gained traction as technology, infrastructure and knowledge have evolved to support their use. New sensor technology revolutionising data collection.

Clinical Trials 81

Clinical Trials Clinical Trials Trials Regulation 81

The Pharma Data

OCTOBER 29, 2020

Data support baricitinib’s ongoing Phase 3 program and potential to be the first approved medicine for people living with alopecia areata (AA). . The data underscore Lilly’s commitment to providing medicines for dermatologic diseases that have high unmet need, including alopecia areata (AA). INDIANAPOLIS , Oct.

Dermatology 52

Dermatology Development Medicine Clinical Trials 52

Drug Discovery World

SEPTEMBER 13, 2022

In the Phase III POETYK PSO-1 and POETYK PSO-2 clinical trials, once-daily Sotyktu showed superior efficacy to placebo and twice-daily Otezla (apremilast) in 1,684 patients aged 18 years and older with moderate-to-severe plaque psoriasis. Psoriasis is a widely prevalent, immune-mediated disease that affects approximately 7.5

FDA Approval 52

FDA Approval Dermatology Clinical Trials Clinical Trials 52

Drug Discovery World

DECEMBER 19, 2022

A double-blind, placebo-controlled clinical trial of a gene therapy gel developed at Stanford Medicine shows improved wound healing in 31 people with the disease, including 19 who were 18 years old or younger. . One trial participant was Vincenzo Mascoli, aged 22. Now he can bathe and sleep on his back without pain. “Now

Gene Therapy 52

Gene Therapy Gene Dermatology Clinical Trials 52

Olympian Clinical Research

FEBRUARY 26, 2021

Clinical trials are research studies designed to evaluate or test a medical, surgical, or behavioral intervention. Most recently, clinical trials have gained recognition through the development and testing of Covid-19 vaccines. Today we’re taking some time to highlight a few of the biggest ones!

Clinical Trials 52

Clinical Trials Clinical Trials Trials Clinical Research 52

XTalks

MAY 26, 2023

The safety and efficacy of Vyjuvek were evaluated in the Phase III randomized, double-blinded, placebo-controlled GEM-3 trial involving 31 patients with DEB, including 30 with the recessive type and one with the dominant type. Results of the trials are published in the journals Nature Medicine and The New England Journal of Medicine.

Gene Therapy 97

Gene Therapy Gene FDA Approval Dermatology 97

pharmaphorum

MAY 18, 2021

Incyte has made further progress with its ruxolitinib cream, notching up a phase 3 trial showing it can re-pigment skin in vitiligo ahead of a key FDA decision in atopic dermatitis. Filings with the FDA and the European Medicines Agency are planned for the second half of this year.

Trials 52

Trials Dermatology FDA Approval Medicine 52

The Pharma Data

OCTOBER 1, 2021

Results from the Phase 3 POETYK PSO-1 and POETYK PSO-2 trials show that response rates for deucravacitinib continued to extend through Week 24 and were maintained through Week 52 in patients with moderate to severe plaque psoriasis. CESTidentified through 52 weeks of knowledge. About Bristol Myers Squibb.

Dermatology 52

Dermatology Trials Clinical Development Research 52

Pharmaceutical Technology

FEBRUARY 28, 2023

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR).

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Clinical Trials Clinical Trials 100

The Pharma Data

NOVEMBER 29, 2021

Applications supported by positive results from the pivotal Phase 3 POETYK-PSO clinical trial program demonstrating superior efficacy of deucravacitinib over Otezla ® (apremilast) and placebo in treating adults with moderate to severe plaque psoriasis. elderly vice chairman of Immunology and Fibrosis Development, Bristol Myers Squibb.

Medicine 52

Medicine Drugs Dermatology Trials 52

Pharmaceutical Technology

FEBRUARY 28, 2023

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR).

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Clinical Trials Clinical Trials 100

Pharmaceutical Technology

FEBRUARY 28, 2023

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR).

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Clinical Trials Clinical Trials 100

Pharmaceutical Technology

FEBRUARY 24, 2023

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. Its investigational medicinal products comprise R-107, R-131 and R-147. The company offers consumer, prescription and automation products.

Contract Manufacturing 100

Contract Manufacturing Dermatology Hormones Production 100

Pharmaceutical Technology

FEBRUARY 24, 2023

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. Its investigational medicinal products comprise R-107, R-131 and R-147. The company offers consumer, prescription and automation products.

Contract Manufacturing 100

Contract Manufacturing Dermatology Hormones Production 100

pharmaphorum

SEPTEMBER 8, 2022

The Digital Medicine Society (DiME) is today releasing a new set of open-access resources to advance the use of nocturnal scratch in the treatment of atopic dermatitis (AD). . It is hoped today’s event will serve as a “blueprint for the broader development and deployment of digital endpoints in medical product development”.

Dermatology 52

Dermatology Production Radiology Development 52

Drug Discovery World

FEBRUARY 16, 2024

Novartis’ Cosentyx (secukinumab) is now available in Scotland, following positive advice from the Scottish Medicines Consortium (SMC). The approval by the SMC is based on robust results from two trials in the largest Phase III programme in HS to date, SUNSHINE and SUNRISE11-13.

Dermatology 64

Dermatology Licensing Licensing Medicine 64

The Pharma Data

AUGUST 16, 2021

Primary and all key secondary endpoints including itch, interference of itch on sleep and quality of life were met at Week 16 in two pivotal Phase 3 trials in lebrikizumab clinical trial program – Safety profile consistent with prior lebrikizumab studies in atopic dermatitis. vice president of immunology development at Lilly.

Dermatology 40

Dermatology Trials Bioavailability Medicine 40

The Pharma Data

MAY 1, 2023

. “The fluctuating symptoms and unpredictable nature of atopic dermatitis, along with limited medicines that can adequately manage long-term uncontrolled symptoms, represent major challenges in the treatment of this chronic disease,” said Jenny Murase, M.D.,

Dermatology 40

Dermatology Medicine Clinical Trials Clinical Trials 40

The Pharma Data

JUNE 7, 2022

The new findings from the Phase 3 clinical trials (ADvocate 1 and 2) showed eight out of ten patients who achieved clinical response (EASI-75*) with lebrikizumab monotherapy at 16 weeks maintained skin clearance at one year of treatment with the once every two weeks or four weeks regimen. About Lebrikizumab.

Trials 40

Trials Clinical Trials Clinical Trials Medicine 40

Drug Discovery World

DECEMBER 13, 2022

Patients who participated in a clinical trial of rocatinlimab showed positive results while taking the drug and up to 20 weeks after stopping therapy, Mount Sinai researchers have reported in The Lancet. . Clinical trial details.

Dermatology 52

Dermatology Clinical Trials Clinical Trials Antibody 52

The Pharma Data

MARCH 29, 2022

The positive 12- and 52-week results from ELEVATE UC 52 follow the recent announcement of positive 12-week findings from the ELEVATE UC 12 trial on March 23. Etrasimod demonstrated a safety profile consistent with previous studies, including the Phase 2 OASIS trial.

Trials 52

Trials Dermatology Development Medicine 52

pharmaphorum

FEBRUARY 3, 2021

He also spent three years before that as Teva’s head of speciality medicines for Europe, and held previous senior roles at AstraZeneca, GSK and Eli Lilly. “Mr For the last three years he has served as executive vice president, growth markets commercial, at Israeli pharma Teva.

Dermatology 52

Dermatology Marketing Branding Medicine 52

Drug Discovery World

FEBRUARY 5, 2024

Williams discussed the advantages of the company’s ‘disease agnostic’ small molecule degraders, and its success so far in translating results from preclinical to clinical tests in dermatology, inflammation and oncology indications. Product launches More than 400 exhibitors are at the event this year, many of whom are launching new products.

Gene Therapy 64

Gene Therapy Life Science Production Dermatology 64

The Pharma Data

NOVEMBER 16, 2020

has sponsored and funded a new FDA Oversight Trial that seeks to restore respiratory function in adults who have suffered lung damage from the COVID-19 virus. Alexander, MD, DMD, FICS is the Principal Investigator, and his office is recruiting patients for enrollment in the trial. Alexander, MD, DMD, FICS.

Trials 52

Trials Clinical Trials Clinical Trials Dermatology 52

ACRP blog

OCTOBER 3, 2023

As reported by the Penn State College of Medicine , six interns spent 11 weeks taking active roles in existing research projects, immersing themselves in the conduct of research, and learning more about careers in clinical research at the college’s home in Hershey, Pa., alongside the Milton S. ACRP member and certificant Kevin Gardner, Jr.,

Clinical Research 59

Clinical Research Research Development Medicine 59

The Pharma Data

MARCH 23, 2022

Statistically significant improvements were achieved in all key secondary endpoints in the trial as well. In the study, etrasimod patients achieved statistically significant improvements in the primary endpoint of clinical remission at week 12 as compared with placebo. The safety profile was consistent with previous Phase 2 studies.

Trials 52

Trials Dermatology Development Medicine 52

Scienmag

MAY 21, 2021

The findings of a clinical trial by Trinity College Dublin researchers of treatment for atopic dermatitis have been published today in The Lancet journal (Friday, 21st May, 2021). Results of the clinical trial at […].

Clinical Trials 43

Clinical Trials Clinical Trials Trials Research 43

pharmaphorum

NOVEMBER 28, 2022

The EC and MHRA approvals are supported by data from the phase 3 ECZTRA 6 trial, and are valid for all European Union Member States, including Ireland and Northern Ireland, as well as Iceland, Norway, and Liechtenstein. The ECZTRA (ECZema TRAlokinumab trial No.6)

Dermatology 52

Dermatology Trials Medicine Antibody 52

XTalks

SEPTEMBER 22, 2022

Clinical Trial Behind Spevigo. The efficacy of Spevigo (spesolimab) was determined based on the results of the Effisayil 1 double-blind, randomized, Phase II clinical trial. Waldman Department of Dermatology. Spevigo is the first approved treatment option for GPP in adults.

FDA Approval 52

FDA Approval Clinical Trials Clinical Trials Dermatology 52

Pharmaceutical Technology

FEBRUARY 18, 2023

According to Globaldata, it is involved in 34 clinical trials, of which 20 were completed, 1 is ongoing, and 13 were terminated. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, immune disorders, and infections, among others.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Antibody Development 100

The Pharma Data

SEPTEMBER 18, 2020

The results mark an improvement in overall response compared to data shared on the drug in this indication back in May, and no new safety signals were observed during the trial. . Sanofi confirmed that these data will be submitted to regulatory authorities in the pursuit of market approval in the US and Europe.

Dermatology 52

Dermatology Trials Medicine Marketing 52

Drug Discovery World

FEBRUARY 2, 2023

The positive opinion is based on results from the Phase III POETYK PSO-1 and POETYK PSO-2 trials, in which Sotyktu demonstrated significant and clinically meaningful improvements in skin clearance, symptom burden and quality of life measures compared to placebo and Otezla.

Medicine 52

Medicine Trials Production Drugs 52